London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
The EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Two European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO.
European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7.
Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Luxembourg-headquartered Covis is taking two COPD drugs off AstraZeneca’s hands in a US$270m deal.
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
German drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.
Institut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.